Physician profile
Marc Cohen
NPI 1376510578
$761,532.32
in general payments reported to CMS, 2019-2025
46 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227K · 2020: $110K · 2021: $157K · 2022: $167K · 2023: $63K · 2024: $36K · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Consulting Fee: $9,698 · Travel and Lodging: $8,043 · Food and Beverage: $5,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,630.00 |
| Consulting Fee | $9,698.00 |
| Travel and Lodging | $8,043.39 |
| Food and Beverage | $5,821.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $336,396.02 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107,964.74 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $94,288.52 | 2019-2024 | Farxiga, Wainua |
| Lilly USA, LLC | $71,270.45 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $58,041.68 | 2019-2022 | |
| Amgen INC. | $32,964.08 | 2019-2025 | Repatha |
| Maquet Cardiovascular L.L.C. | $15,694.84 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $9,750.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $8,407.98 | 2019-2025 | |
| Sanofi US Services INC. | $6,876.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $6,140.60 | 2019-2023 | Camzyos |
| Astrazeneca Uk Limited | $4,833.00 | 2023 | Brilinta |
| Edwards Lifesciences Corporation | $2,343.11 | 2021-2023 | |
| Getinge USA Sales, LLC | $1,600.00 | 2020 | |
| Boston Scientific Corporation | $777.00 | 2019-2025 | Rotapro, Comet, Avvigo Guidance System |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $633.04 | 2022-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Idorsia Pharmaceuticals US INC | $604.53 | 2025 | Tryvio, Tryvio |
| Janssen Scientific Affairs, LLC | $599.96 | 2019-2024 | Xarelto |
| Abiomed | $424.94 | 2019-2025 | Impella |
| Medtronic, INC. | $305.74 | 2024-2025 | Symplicity G3, Endurant Iis |
| Heartflow, INC. | $248.96 | 2025 | |
| Abbott Laboratories | $170.81 | 2025 | Aveir |
| Endologix LLC | $161.28 | 2023-2024 | Alto Abdominal Stent Graft System, Endocross Device, Torus Stent Graft System |
| Medtronic Vascular, INC. | $136.59 | 2019 | |
| Philips North America LLC | $123.00 | 2023-2025 | (Ao0) Igt Devices Intracardiac, Extended Holter |
| Ekos Corporation | $109.34 | 2019 | |
| Datascope Corp. | $89.92 | 2021 | |
| Pfizer INC. | $75.93 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $72.67 | 2021-2022 | |
| Spinal Simplicity, LLC | $60.37 | 2025 | Ha Minuteman G3-R |
| Cardiva Medical, INC. | $49.85 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire |
| Baxter Healthcare | $49.17 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Stryker Corporation | $39.12 | 2025 | Artix Mt |
| Cardiovascular Systems INC. | $32.33 | 2020 | |
| Imperative Care, INC | $27.51 | 2025 | Symphony Catheter |
| Atricure, INC. | $26.57 | 2025 | Atriclip Laa Exclusion System |
| Acist Medical Systems, INC. | $21.35 | 2022 | |
| Chiesi USA, INC. | $18.55 | 2025 | Filsuvez |
| Merck Sharp & Dohme LLC | $17.43 | 2025 | Verquvo |
| Cagent Vascular INC | $17.04 | 2023 | Serrantor |
| Kiniksa Pharmaceuticals, Ltd. | $15.18 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $14.86 | 2020 | |
| Portola Pharmaceuticals, LLC | $12.85 | 2020 | |
| Melinta Therapeutics, LLC | $12.68 | 2019 | |
| Bard Peripheral Vascular, INC. | $12.23 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.